Non-Small Cell Lung Cancer (NSCLC)

Panelists discuss how the MARIPOSA study demonstrated significant progression-free survival and overall survival (OS) benefits with amivantamab plus lazertinib vs osimertinib monotherapy, with mature overall survival data showing a 25% improvement in survival outcomes.

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

Jorge Nieva, MD, discusses how clinical experience has shown that taletrectinib is manageable and can elicit responses in patients with ROS1-positive non–small cell lung cancer.

Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer has evolved to include 3 viable frontline options (osimertinib alone, osimertinib plus chemotherapy, and amivantamab plus lazertinib), with treatment selection based on patient characteristics, preferences, and physician judgment rather than a strict algorithmic approach.

Panelists discuss how a 46-year-old graphic designer with stage IV EGFR-mutant non–small cell lung cancer and brain metastases was successfully treated with amivantamab plus lazertinib after weighing multiple frontline treatment options.

AI transforms non-small cell lung cancer management, enhancing diagnostics, treatment predictions, and personalized care strategies for improved patient outcomes.

Developers plan to begin a rolling new drug application for zidesamtinib as a treatment for this non–small cell lung cancer population in July 2025.

The decision is supported by results from the phase 2 TROPION-Lung05 and phase 3 TROPION-Lung01 trials.

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.

Experts from Washington University in St Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.

Sacituzumab tirumotecan showed a manageable safety profile compared to docetaxel in patients with EGFR-mutant advanced non–small cell lung cancer.

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Among 44 patients with EGFR-positive non–small cell lung cancer who discontinued docetaxel, 36.4% crossed over to the sac-TMT arm.

The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

Results from CheckMate-816 could be practice-changing after an OS improvement was noted with NAT nivolumab plus chemotherapy in resectable NSCLC.

Efficacy and biomarker analyses from CheckMate-77T support perioperative nivolumab as an effective option in resectable NSCLC.

An efficacy advantage with osimertinib-containing regimens was consistent across predefined patient subgroups in those with EGFR-mutant NSCLC.

Most patients who received COCOON dermatologic management reported mild or no dermatologic symptoms following treatment with amivantamab/lazertinib.

Data from SACHI support savolitinib/osimertinib as a chemotherapy-free option in previously treated EGFR-mutated NSCLC harboring a MET amplification.

Results from HERTHENA-Lung02 did not show improved OS with HER3-DXd for patients with EGFR-mutated NSCLC.

Among 2 patient subgroups with advanced, HER2-mutant non–small cell lung cancer, sevabertinib showed comparable objective response rates.

Results from the KRYSTAL-7 trial showed that efficacy was improved with adagrasib/pembrolizumab for KRAS G12C-mutated NSCLC.